ERBB2 and breast cancer: The performance of scPharm was comprehensively assessed across various datasets, including scRNA‐seq data from ER‐positive and HER2‐positive breast cancer tissues, PC9 cells treated with erlotinib at different time points, and the MMTV‐PyMT mouse mammary tumour model.